(2S)-2-{[(1R)-2-Amino-1-methylethyl]oxy}-3-{1-[4-(cyclohexyloxy)phenyl]-1H-imidazol-4-yl}propanoic acid | 570398-07-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2S)-2-{[(1R)-2-Amino-1-methylethyl]oxy}-3-{1-[4-(cyclohexyloxy)phenyl]-1H-imidazol-4-yl}propanoic acid
• 英文别名: (2S)-2-[(2R)-1-aminopropan-2-yl]oxy-3-[1-(4-cyclohexyloxyphenyl)imidazol-4-yl]propanoic acid
• CAS: 570398-07-1
• 化学式: C₂₁H₂₉N₃O₄
• 分子量: 387.479
• InChiKey: JDWQDFASLNRSJZ-QRWLVFNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  99.6
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• 3-(Imidazolyl)-2-alkoxypropanoic acids
  申请人：Pfizer Inc.

  公开号：US20030199522A1

  公开（公告）日：2003-10-23

  Compounds according to formula (I) wherein n is 0-3, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R 5 and R 8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  根据公式（I）中的化合物，其中n为0-3，R1为可选择的取代C1-6烷基，C2-6烯基或C2-6炔基，杂环，芳香杂环，芳基或氢，而R2、R3、R4、R5、R6、R7、R8和R9分别独立选择自氢和可选择取代的C1-6烷基，或R5和R8为烷基链，是新颖的。它们在治疗与纤维蛋白沉积相关的血栓性疾病和其他病理条件中具有用途。
• US6713496B2
  申请人：——

  公开号：US6713496B2

  公开（公告）日：2004-03-30
• US6958402B2
  申请人：——

  公开号：US6958402B2

  公开（公告）日：2005-10-25
• [EN] 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS<br/>[FR] ACIDES 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIQUES SERVANT D'INHIBITEURS TAFIA
  申请人：PFIZER LTD

  公开号：WO2003061652A1

  公开（公告）日：2003-07-31

  Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R5 and R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.